We found significant enrichment of BG-PVS genes in targets for anti-infectives, driven by CRHR1 (chr17q21.31, target for telavancin), and for diseases of the nervous system, driven by MAPT (chr17q21.31, target for davunetide); and of HIP-PVS genes in targets for ear disease drugs, driven by SERPIND1 (chr22q11.21, target for sulodexide, also used for venous thrombosis prevention; Extended Data Figs. 6 and 7). This evidence concerns the gene MAPT and disorder of ear.